-
-
-
-
-
-
-
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
-
-
-
-
-
-
-
Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
-
-
-
-
-
-
-
UPDATE: Mereo BioPharma (MREO) Receives FDA Fast Track Designation for Navicixizumab for Treatment of Heavily Pretreated Ovarian Cancer
-
-
-
-
-
-
-
Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
-
-
-
-
-
-
-
Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
-
-
-
-
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

